<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481402</url>
  </required_header>
  <id_info>
    <org_study_id>HerlevH</org_study_id>
    <nct_id>NCT01481402</nct_id>
  </id_info>
  <brief_title>Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)</brief_title>
  <acronym>LIHFA</acronym>
  <official_title>Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Faber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The purpose of the study is to examine if treatment with liothyronine increases left
      ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the
      examination is performed, they begin the study medication while admitted at Dept. of
      Cardiology, Herlev Hospital, for cardiac monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LVEF</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of liothyronine treatment in low dose in 3 months on LVEF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of 3 months low dose liothyronine treatment on body composition in patients with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of 3 months low dose liothyronine treatment on quality of life assessed by SF-36 and Minnesota Living with Heart Failure questionnaires in patients with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>YKL-40, YNF-alpha, hsCRP and IL-6</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of 3 months low dose liothyronine treatment on low grade inflammation assessed by measurement of pro-inflammatory markers in patients with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBP 4, HBA1C, adiponectin (high and low weight), glucose and HOMA-1</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of 3 months low dose liothyronine treatment on metabolic status in patients with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GDF 8, SHBG, CK and PINP</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of 3 months low dose liothyronine treatment on the extrathyroidal thyroid effect in patients with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP, EDV and ESV</measure>
    <time_frame>3 months</time_frame>
    <description>The effect of 3 months low dose liothyronine treatment on heart function in patients with heart failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Heart Failure</condition>
  <condition>Low T3 Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo-liothyronine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 months of placebo followed by 3 months of Liothyronine treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liothyronine-Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 months of Liothyronine treatment followed by 3 months of Placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>Liothyronine 40 microgram per day</description>
    <arm_group_label>Placebo-liothyronine</arm_group_label>
    <other_name>T3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)</description>
    <arm_group_label>Liothyronine-Placebo</arm_group_label>
    <other_name>T3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable, chronic systolic heart failure

          -  T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal

          -  LVEF ≤ 45 % on prior echocardiography

        Exclusion Criteria:

          -  Established thyroid illness

          -  Atrial fibrillation/flutter

          -  More than 20% ventricular extrasystoles

          -  Severe chronic obstructive lung disorder

          -  Pregnancy. Pregnancy testing will be done for fertile women

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Faber, MDSci</last_name>
    <role>Study Director</role>
    <affiliation>Herlev Hospital, Dept. of Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital, Dept. of Endocrinology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Jens Faber</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Liothyronine</keyword>
  <keyword>Low T3 syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Euthyroid Sick Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

